Journal of Hepatology
Volume 52, Issue 3 , Pages 432-440 , March 2010

Congenital disorders of glycosylation in hepatology: The example of polycystic liver disease

  • Manoe J. Janssen

      Affiliations

    • Department of Gastroenterology and Hepatology, Institute for Genetic & Metabolic Disease, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • ,
  • Esmé Waanders

      Affiliations

    • Department of Gastroenterology and Hepatology, Institute for Genetic & Metabolic Disease, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • Department of Human Genetics, Institute for Genetic & Metabolic Disease, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    • ,
  • Jannes Woudenberg

      Affiliations

    • Department of Gastroenterology and Hepatology, Institute for Genetic & Metabolic Disease, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • ,
  • Dirk J. Lefeber

      Affiliations

    • Department of Neurology, Institute for Genetic & Metabolic Disease, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    • Department of Laboratory Medicine, Institute for Genetic & Metabolic Disease, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • ,
  • Joost P.H. Drenth

      Affiliations

    • Department of Gastroenterology and Hepatology, Institute for Genetic & Metabolic Disease, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 24 3614760; fax: +31 24 3540103.

References 

  1. Blomme B, Van SC, Callewaert N, Van VH. Alteration of protein glycosylation in liver diseases. J Hepatol. 2009;50:592–603
  2. Everson GT, Taylor MR, Doctor RB. Polycystic disease of the liver. Hepatology. 2004;40:774–782
  3. Masyuk T, LaRusso N. Polycystic liver disease: new insights into disease pathogenesis. Hepatology. 2006;43:906–908
  4. Kida T, Nakanuma Y, Terada T. Cystic dilatation of peribiliary glands in livers with adult polycystic disease and livers with solitary nonparasitic cysts: an autopsy study. Hepatology. 1992;16:334–340
  5. Qian Q, Li A, King BF, Kamath PS, Lager DJ, Huston J, et al. Clinical profile of autosomal dominant polycystic liver disease. Hepatology. 2003;37:164–171
  6. Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology. 2004;127:1565–1577
  7. Drenth JP, Martina JA, van de KR, Bonifacino JS, Jansen JB. Polycystic liver disease is a disorder of cotranslational protein processing. Trends Mol Med. 2005;11:37–42
  8. Hoevenaren IA, Wester R, Schrier RW, McFann K, Doctor RB, Drenth JP, et al. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int. 2008;28:264–270
  9. Van Keimpema L, de Koning DB, Strijk SP, Drenth JP. Aspiration-sclerotherapy results in effective control of liver volume in patients with liver cysts. Dig Dis Sci. 2008;53:2251–2257
  10. Van Keimpema L, Ruurda JP, Ernst MF, van Geffen HJ, Drenth JP. Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%. J Gastrointest Surg. 2008;12:477–482
  11. Van Keimpema L, Hockerstedt K. Treatment of polycystic livers. Br J Surg. 2009;96:1379–1380
  12. Van Keimpema L, Nevens F, Adam R, Porte R, Kirkegaard P, Metselaar H, et al. Liver transplantation in isolated polycystic liver disease. Transpl Int. 2009;22:3
  13. Van Keimpema L, Nevens F, Vanslembrouck R, Van Oijen MGH, Hoffmann AL, Dekker HM, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009;137:1661–1668
  14. Drenth JP, te Morsche RH, Smink R, Bonifacino JS, Jansen JB. Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat Genet. 2003;33:345–347
  15. Li A, Davila S, Furu L, Qian Q, Tian X, Kamath PS, et al. Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet. 2003;72:691–703
  16. Davila S, Furu L, Gharavi AG, Tian X, Onoe T, Qian Q, et al. Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet. 2004;36:575–577
  17. Brodsky JL, Goeckeler J, Schekman R. BiP and Sec63p are required for both co- and posttranslational protein translocation into the yeast endoplasmic reticulum. Proc Natl Acad Sci USA. 1995;92:9643–9646
  18. Rapoport TA. Protein translocation across the eukaryotic endoplasmic reticulum and bacterial plasma membranes. Nature. 2007;450:663–669
  19. Young BP, Craven RA, Reid PJ, Willer M, Stirling CJ. Sec63p and Kar2p are required for the translocation of SRP-dependent precursors into the yeast endoplasmic reticulum in vivo. EMBO J. 2001;20:262–271
  20. Wang X, Johnsson N. Protein kinase CK2 phosphorylates Sec63p to stimulate the assembly of the endoplasmic reticulum protein translocation apparatus. J Cell Sci. 2005;118:723–732
  21. Jermy AJ, Willer M, Davis E, Wilkinson BM, Stirling CJ. The Brl domain in Sec63p is required for assembly of functional endoplasmic reticulum translocons. J Biol Chem. 2006;281:7899–7906
  22. Willer M, Jermy AJ, Young BP, Stirling CJ. Identification of novel protein–protein interactions at the cytosolic surface of the Sec63 complex in the yeast ER membrane. Yeast. 2003;20:133–148
  23. Lyman SK, Schekman R. Binding of secretory precursor polypeptides to a translocon subcomplex is regulated by BiP. Cell. 1997;88:85–96
  24. Matlack KE, Misselwitz B, Plath K, Rapoport TA. BiP acts as a molecular ratchet during posttranslational transport of prepro-alpha factor across the ER membrane. Cell. 1999;97:553–564
  25. Brodsky JL, Schekman R. A Sec63p-BiP complex from yeast is required for protein translocation in a reconstituted proteoliposome. J Cell Biol. 1993;123:1355–1363
  26. Corsi AK, Schekman R. The lumenal domain of Sec63p stimulates the ATPase activity of BiP and mediates BiP recruitment to the translocon in Saccharomyces cerevisiae. J Cell Biol. 1997;137:1483–1493
  27. Willer M, Jermy AJ, Steel GJ, Garside HJ, Carter S, Stirling CJ. An in vitro assay using overexpressed yeast SRP demonstrates that cotranslational translocation is dependent upon the J-domain of Sec63p. Biochemistry. 2003;42:7171–7177
  28. McCracken AA, Brodsky JL. Assembly of ER-associated protein degradation in vitro: dependence on cytosol, calnexin, and ATP. J Cell Biol. 1996;132:291–298
  29. Ng W, Sergeyenko T, Zeng N, Brown JD, Romisch K. Characterization of the proteasome interaction with the Sec61 channel in the endoplasmic reticulum. J Cell Sci. 2007;120:682–691
  30. Plemper RK, Bohmler S, Bordallo J, Sommer T, Wolf DH. Mutant analysis links the translocon and BiP to retrograde protein transport for ER degradation. Nature. 1997;388:891–895
  31. Hendershot LM. The ER chaperone BiP is a master regulator of ER function. Mt Sinai J Med. 2004;71:289–297
  32. Gillece P, Pilon M, Romisch K. The protein translocation channel mediates glycopeptide export across the endoplasmic reticulum membrane. Proc Natl Acad Sci USA. 2000;97:4609–4614
  33. Alder NN, Shen Y, Brodsky JL, Hendershot LM, Johnson AE. The molecular mechanisms underlying BiP-mediated gating of the Sec61 translocon of the endoplasmic reticulum. J Cell Biol. 2005;168:389–399
  34. Hamman BD, Hendershot LM, Johnson AE. BiP maintains the permeability barrier of the ER membrane by sealing the lumenal end of the translocon pore before and early in translocation. Cell. 1998;92:747–758
  35. Meyer HA, Grau H, Kraft R, Kostka S, Prehn S, Kalies KU, et al. Mammalian Sec61 is associated with Sec62 and Sec63. J Biol Chem. 2000;275:14550–14557
  36. Tyedmers J, Lerner M, Bies C, Dudek J, Skowronek MH, Haas IG, et al. Homologs of the yeast Sec complex subunits Sec62p and Sec63p are abundant proteins in dog pancreas microsomes. Proc Natl Acad Sci USA. 2000;97:7214–7219
  37. Kawaai K, Hisatsune C, Kuroda Y, Mizutani A, Tashiro T, Mikoshiba K. 80K-H interacts with inositol 1,4,5-trisphosphate (IP3) receptors and regulates IP3-induced calcium release activity. J Biol Chem. 2009;284:372–380
  38. Li YM, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A, et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA. 1996;93:11047–11052
  39. Gkika D, Mahieu F, Nilius B, Hoenderop JG, Bindels RJ. 80K-H as a new Ca2+ sensor regulating the activity of the epithelial Ca2+ channel transient receptor potential cation channel V5 (TRPV5). J Biol Chem. 2004;279:26351–26357
  40. Brule S, Faure R, Dore M, Silversides DW, Lussier JG. Immunolocalization of vacuolar system-associated protein-60 (VASAP-60). Histochem Cell Biol. 2003;119:371–381
  41. Hodgkinson CP, Mander A, Sale GJ. Identification of 80K-H as a protein involved in GLUT4 vesicle trafficking. Biochem J. 2005;388:785–793
  42. Kanai M, Goke M, Tsunekawa S, Podolsky DK. Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein. J Biol Chem. 1997;272:6621–6628
  43. Forough R, Lindner L, Partridge C, Jones B, Guy G, Clark G. Elevated 80K-H protein in breast cancer: a role for FGF-1 stimulation of 80K-H. Int J Biol Markers. 2003;18:89–98
  44. Waanders E, Croes HJ, Maass CN, te Morsche RH, van Geffen HJ, Van Krieken JH, et al. Cysts of PRKCSH mutated polycystic liver disease patients lack hepatocystin but express Sec63p. Histochem Cell Biol. 2008;129:301–310
  45. Trombetta ES, Simons JF, Helenius A. Endoplasmic reticulum glucosidase II is composed of a catalytic subunit, conserved from yeast to mammals, and a tightly bound noncatalytic HDEL-containing subunit. J Biol Chem. 1996;271:27509–27516
  46. Trombetta ES, Fleming KG, Helenius A. Quaternary and domain structure of glycoprotein processing glucosidase II. Biochemistry. 2001;40:10717–10722
  47. Anelli T, Sitia R. Protein quality control in the early secretory pathway. EMBO J. 2008;27:315–327
  48. Deprez P, Gautschi M, Helenius A. More than one glycan is needed for ER glucosidase II to allow entry of glycoproteins into the calnexin/calreticulin cycle. Mol Cell. 2005;19:183–195
  49. Ruddock LW, Molinari M. N-Glycan processing in ER quality control. J Cell Sci. 2006;119:4373–4380
  50. D’Alessio C, Fernandez F, Trombetta ES, Parodi AJ. Genetic evidence for the heterodimeric structure of glucosidase II. The effect of disrupting the subunit-encoding genes on glycoprotein folding. J Biol Chem. 1999;274:25899–25905
  51. Wilkinson BM, Purswani J, Stirling CJ. Yeast GTB1 encodes a subunit of glucosidase II required for glycoprotein processing in the endoplasmic reticulum. J Biol Chem. 2006;281:6325–6333
  52. Pelletier MF, Marcil A, Sevigny G, Jakob CA, Tessier DC, Chevet E, et al. The heterodimeric structure of glucosidase II is required for its activity, solubility, and localization in vivo. Glycobiology. 2000;10:815–827
  53. Treml K, Meimaroglou D, Hentges A, Bause E. The alpha- and beta-subunits are required for expression of catalytic activity in the hetero-dimeric glucosidase II complex from human liver. Glycobiology. 2000;10:493–502
  54. Waanders E, Lameris AL, Op den Camp HJ, Pluk W, Gloerich J, Strijk SP, et al. Hepatocystin is not secreted in cyst fluid of hepatocystin mutant polycystic liver patients. J Proteome Res. 2008;7:2490–2495
  55. Stigliano ID, Caramelo JJ, Labriola CA, Parodi AJ, D’Alessio C. Glucosidase II beta subunit modulates N-glycan trimming in fission yeasts and mammals. Mol Biol Cell. 2009;20:3974–3984
  56. Waanders E, Van Krieken JH, Lameris AL, Drenth JP. Disrupted cell adhesion but not proliferation mediates cyst formation in polycystic liver disease. Mod Pathol. 2008;21:1293–1302
  57. Jacob GS. Glycosylation inhibitors in biology and medicine. Curr Opin Struct Biol. 1995;5:605–611
  58. Arendt CW, Dawicki W, Ostergaard HL. Alternative splicing of transcripts encoding the alpha- and beta-subunits of mouse glucosidase II in T lymphocytes. Glycobiology. 1999;9:277–283
  59. Mehta A, Zitzmann N, Rudd PM, Block TM, Dwek RA. Alpha-glucosidase inhibitors as potential broad based anti-viral agents. FEBS Lett. 1998;430:17–22
  60. Free RB, Hazelwood LA, Cabrera DM, Spalding HN, Namkung Y, Rankin ML, et al. D-1 and D-2 dopamine receptor expression is regulated by direct interaction with the chaperone protein calnexin. J Biol Chem. 2007;282:21285–21300
  61. Baldwin TA, Gogela-Spehar M, Ostergaard HL. Specific isoforms of the resident endoplasmic reticulum protein glucosidase II associate with the CD45 protein–tyrosine phosphatase via a lectin-like interaction. J Biol Chem. 2000;275:32071–32076
  62. Harada Y, Li H, Li H, Lennarz WJ. Oligosaccharyltransferase directly binds to ribosome at a location near the translocon-binding site. Proc Natl Acad Sci USA. 2009;106:6945–6949
  63. Sun L, Eklund EA, Chung WK, Wang C, Cohen J, Freeze HH. Congenital disorder of glycosylation id presenting with hyperinsulinemic hypoglycemia and islet cell hyperplasia. J Clin Endocrinol Metab. 2005;90:4371–4375
  64. Kranz C, Sun L, Eklund EA, Krasnewich D, Casey JR, Freeze HH. CDG-Id in two siblings with partially different phenotypes. Am J Med Genet A. 2007;143A:1414–1420
  65. Denecke J, Kranz C, Kemming D, Koch HG, Marquardt T. An activated 5′ cryptic splice site in the human ALG3 gene generates a premature termination codon insensitive to nonsense-mediated mRNA decay in a new case of congenital disorder of glycosylation type Id (CDG-Id). Hum Mutat. 2004;23:477–486
  66. Weinstein M, Schollen E, Matthijs G, Neupert C, Hennet T, Grubenmann CE, et al. CDG-IL: an infant with a novel mutation in the ALG9 gene and additional phenotypic features. Am J Med Genet A. 2005;136:194–197
  67. Frank CG, Grubenmann CE, Eyaid W, Berger EG, Aebi M, Hennet T. Identification and functional analysis of a defect in the human ALG9 gene: definition of congenital disorder of glycosylation type IL. Am J Hum Genet. 2004;75:146–150
  68. Vleugels W, Keldermans L, Jaeken J, Butters TD, Michalski JC, Matthijs G, et al. Quality control of glycoproteins bearing truncated glycans in an ALG9-defective (CDG-IL) patient. Glycobiology. 2009;19:910–917
  69. Eklund EA, Newell JW, Sun L, Seo NS, Alper G, Willert J, et al. Molecular and clinical description of the first US patients with congenital disorder of glycosylation Ig. Mol Genet Metab. 2005;84:25–31
  70. Grubenmann CE, Frank CG, Kjaergaard S, Berger EG, Aebi M, Hennet T. ALG12 mannosyltransferase defect in congenital disorder of glycosylation type lg. Hum Mol Genet. 2002;11:2331–2339
  71. Kranz C, Basinger AA, Gucsavas-Calikoglu M, Sun L, Powell CM, Henderson FW, et al. Expanding spectrum of congenital disorder of glycosylation Ig (CDG-Ig): sibs with a unique skeletal dysplasia, hypogammaglobulinemia, cardiomyopathy, genital malformations, and early lethality. Am J Med Genet A. 2007;143A:1371–1378
  72. Damen G, de KH, Huijmans J, den HJ, Sinaasappel M. Gastrointestinal and other clinical manifestations in 17 children with congenital disorders of glycosylation type Ia, Ib, and Ic. J Pediatr Gastroenterol Nutr. 2004;38:282–287
  73. Eklund EA, Sun L, Yang SP, Pasion RM, Thorland EC, Freeze HH. Congenital disorder of glycosylation Ic due to a de novo deletion and an hALG-6 mutation. Biochem Biophys Res Commun. 2006;339:755–760
  74. Grunewald S, De VR, Jaeken J. Abnormal lysosomal inclusions in liver hepatocytes but not in fibroblasts in congenital disorders of glycosylation (CDG). J Inherit Metab Dis. 2003;26:49–54
  75. Chantret I, Dancourt J, Dupre T, Delenda C, Bucher S, Vuillaumier-Barrot S, et al. A deficiency in dolichyl-P-glucose:Glc1Man9GlcNAc2-PP-dolichyl alpha3-glucosyltransferase defines a new subtype of congenital disorders of glycosylation. J Biol Chem. 2003;278:9962–9971
  76. Eklund EA, Sun L, Westphal V, Northrop JL, Freeze HH, Scaglia F. Congenital disorder of glycosylation (CDG)-Ih patient with a severe hepato-intestinal phenotype and evolving central nervous system pathology. J Pediatr. 2005;147:847–850
  77. Schollen E, Frank CG, Keldermans L, Reyntjens R, Grubenmann CE, Clayton PT, et al. Clinical and molecular features of three patients with congenital disorders of glycosylation type Ih (CDG-Ih) (ALG8 deficiency). J Med Genet. 2004;41:550–556
  78. De Praeter CM, Gerwig GJ, Bause E, Nuytinck LK, Vliegenthart JF, Breuer W, et al. A novel disorder caused by defective biosynthesis of N-linked oligosaccharides due to glucosidase I deficiency. Am J Hum Genet. 2000;66:1744–1756
  79. Bovee JV, Cleton-Jansen AM, Wuyts W, Caethoven G, Taminiau AH, Bakker E, et al. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet. 1999;65:689–698
  80. Pei Y, Watnick T, He N, Wang K, Liang Y, Parfrey P, et al. Somatic PKD2 mutations in individual kidney and liver cysts support a “two-hit” model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1999;10:1524–1529
  81. Waanders E, te Morsche RH, de Man RA, Jansen JB, Drenth JP. Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease. Hum Mutat. 2006;27:830
  82. Haeuptle MA, Pujol FM, Neupert C, Winchester B, Kastaniotis AJ, Aebi M, et al. Human RFT1 deficiency leads to a disorder of N-linked glycosylation. Am J Hum Genet. 2008;82:600–606
  83. Iancu TC, Mahajnah M, Manov I, Cherurg S, Knopf C, Mandel H. The liver in congenital disorders of glycosylation: ultrastructural features. Ultrastruct Pathol. 2007;31:189–197

PII: S0168-8278(09)00812-5

doi: 10.1016/j.jhep.2009.12.011

Journal of Hepatology
Volume 52, Issue 3 , Pages 432-440 , March 2010

Article Tools

* Image Usage & Resolution